Skip to main content

Recombinant Human F13A1 His-tag Protein, CF

Catalog # 10179-F1 | R&D Systems, Inc. a Bio-Techne Brand
Catalog #
Availability
Size / Price
Qty
Loading...
10179-F1-050

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

Conjugate

Unconjugated

Applications

Enzyme Activity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human F13A1 protein
Ser2-Met732
with an N-terminal Met and 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

No results obtained, Met predicted. Protein identity confirmed by MS analysis of tryptic fragments.

Predicted Molecular Mass

84 kDa

SDS-PAGE

76-88 kDa, under reducing conditions

Activity

Measured by its ability to release DNP from Abz-NE(CAD-DNP)EQVSPLTLLK-OH.
The specific activity is >13.0 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human F13A1 His-tag Protein, CF

Recombinant Human F13A1 His-tag Protein Enzyme Activity

Recombinant Human F13A1 His-tag Protein Enzyme Activity

Recombinant Human F13A1 His-tag (Catalog # 10179-F1) is measured by its ability to release DNP from Abz-NE(CAD-DNP)EQVSPLTLLK-OH. The activity (orange) is approximately 2-fold higher than the competitor's F13A1 (green).
Recombinant Human F13A1 His-tag Protein SDS-PAGE

Recombinant Human F13A1 His-tag Protein SDS-PAGE

2 μg/lane of Recombinant Human F13A1 His-tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing a band at ~82 kDa under reducing conditions.

Formulation, Preparation and Storage

10179-F1
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, EDTA, Glycerol and TCEP.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: F13A1

Coagulation Factor XIIIa1 (F13a1) is a member of the transglutaminase family which includes F13A1 and TGM1-7 (1). F13 in the plasma is a tetrameric complex composed of two alpha (A) and two beta (B) chains where the A subunit is a transglutaminase zymogen and the B subunit is an inhibitory glycoprotein with no enzymatic function (2).  Activation by thrombin and calcium ions results in the formation of the catalytically active transglutaminase F13a composed of an alpha chain homodimer capable of forming gamma-glutamyl-epsilon-lysine cross-links. The 83 kDa F13a monomer has an N-terminal activation peptide and a beta sandwich preceding the catalytic core with catalytic triad active site and two C-terminal beta barrels (3). The active homodimer is intracellular in platelets, megakaryocytes, monocytes and macrophages. The primary physiological outcome of the catalytic activity of F13a is cross-linking of fibrin and anti-plasmin to stabilize the fibrin clot (4,5). However, in addition to cross-linking fibrin, F13a is capable of cross-linking many substrates involved in complement activation, coagulation, inflammatory and immune responses and extracellular matrix organization (6). Cross-linking of key substrates by F13a has been directly shown to play a role in in atherosclerosis (7), wound healing (8), angiogenesis (9,10), maintaining pregnancy (11), ECM deposition, osteoblast differentiation and bone remodeling (12), and immune defense (13). F13A has also been detected as a marker in acute promyelocytic leukemia (APL)(14) and expression is considered of value for diagnosis and prognosis for leukemia-associated immunophenotype. Congenital deficiency results in bleeding manifestations including intercranial hemorrhage (15), poor wound healing (17), and spontaneous abortions (17) that can be treated with F13 (18).

References

  1. Griffin, M. et al. (2002) Biochem. J. 368:377.
  2. Muszbek, L. et al. (1999) Thromb. Res. 94:271.
  3. Yee, V. C. et al. (1994) Proc. Natl. Acad. Sci. USA 91:7296.
  4. Lord, S. T. et al. (2011) Aterioscler. Thromb. Vasc. Biol. 31:494.
  5. Fraser, S. R. et al. (2011) Blood 117:6371.
  6. Nikolajsen, C. L. et al. (2014) J. Biol. Chem. 289:6526.
  7. AbdAlla, S. et al. (2004) Cell. 119:343.
  8. Nahrendorf, M. et al. (2006) Circulation 113:1196.
  9. Dardik, R. et al. (2006) Thromb. Haemost. 95:546.
  10. Dardik, R. et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25:526
  11. Asahina, T. et al. (2000) Placenta. 21:388.
  12. Piercy-Kotb, S. A. et al. (2012) J. Cell Physiol. 227:2936.
  13. Richardson, V. R. et al. (2012) Br. J. Haematol. 160:116.
  14. Simon, A. et al. (2012) Cytometry B. Clin. Cytom. 82:209.
  15. Naderi, M. et al. (2015) Hematology. 20:112.
  16. Inbal, A. et al. (2005) Thromb. Haemost. 94:432.
  17. Inbal, A. and L. Muszbek. (2003) Semin. Thromb. Hemost. 29:171
  18. Naderi, M. et al. (2016) Iran J. Pharm. Res. 15:635.

Long Name

Coagulation Factor XIII, A1 Polypeptide

Alternate Names

F13A, FSF, A Subunit

Entrez Gene IDs

2162 (Human)

Gene Symbol

F13A1

UniProt

Product Documents for Recombinant Human F13A1 His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human F13A1 His-tag Protein, CF

For research use only

Loading...
Setting the standard in quality research reagents